Tough choices: Private sale of drugs in public hospitals

CMAJ. Canadian Medical Association Journal

Volumn 182, Issue 4, 2010, Pages 374-376

  Flood, Colleen M ^a,b   Hardcastle, Lorian ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b CANADIAN INSTITUTES OF HEALTH RESEARCH   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; IBRITUMOMAB TIUXETAN; TRASTUZUMAB; DRUG;

CLINICAL TRIAL; DRUG COST; DRUG LEGISLATION; DRUG MARKETING; FUNDING; HEALTH CARE; HEALTH CARE SYSTEM; HOSPITAL POLICY; HUMAN; MULTICENTER STUDY; PUBLIC HEALTH INSURANCE; PUBLIC HOSPITAL; REVIEW; CANADA; COMMERCIAL PHENOMENA; ECONOMICS; EPIDEMIOLOGY; HEALTH CARE DISPARITY; HEALTH CARE POLICY; LEGISLATION AND JURISPRUDENCE; ORGANIZATION; ORGANIZATION AND MANAGEMENT; PUBLIC HEALTH; STATISTICS AND NUMERICAL DATA;

CANADA; COMMERCE; DECISION MAKING, ORGANIZATIONAL; HEALTH POLICY; HEALTHCARE DISPARITIES; HOSPITALS, PUBLIC; LEGISLATION, DRUG; NATIONAL HEALTH PROGRAMS; PHARMACEUTICAL PREPARATIONS; PRIVATE SECTOR;

EID: 77953319419     PISSN: 08203946     EISSN: 14882329     Source Type: Journal    
DOI: 10.1503/cmaj.081137     Document Type: Article

References (22)

1. Laupacis A. Inclusion of drugs in provincial drug benefit programs: who is making these decisions and are they the right ones? CMAJ 2002;166:44-47
2. Benzie R. Big cancer bills covered. Toronto Star Healthzone. 2008 July 2. Available: http://healthzone.ca/health/article/452457 (accessed 2009 Dec. 15).
3. Chafe R, Dhalla IA, Dobrow M, et al. Accessing unfunded cancer drugs in publicly funded hospitals. Lancet Oncol 2009;10:306-307
4. Kolata G, Pollack A. Costly cancer drug offers hope, but also a dilemma. New York Times. 2008 July 6. Available: www.nytimes.com/2008/07/06/health /06 avastin.html?-r=2&adxnnl=1&oref=slogin&adxnnlx=1216059031- GQpQGOvi7tC6 TBHJWt+7cg (accessed 2009 Dec. 15).
5. Canada Health Act, R.S.C. 1985, c. C-6, s. 2, 7, 9.
6. Choudhry S. Bill 11, the Canada Health Act and the social union: the need for institutions. Osgoode Hall Law J 2000;38:39-76.
7. Commitment to the Future of Medicare Act, S.O. 2004, c. 5, s. 10(5).
8. Health Insurance Act, R.S.O. 1990, c. H-6, s. 11.2(1)
9. and General Regulation, R.R.O. 1990, Reg 552, s 7.
10. Health Insurance Act, R.S.O. 1990, c. H-6, s. 11.2(1) and
11. General Regulation, R.R.O. 1990, Reg 552, s 8.
12. Khoo K, Colucci R, Hryniuk W, et al. The new wave of cancer drugs. In: Report card on cancer in Canada. Vol 10. Toronto (ON): Cancer Advocacy Coalition; 2007. p. 43.
13. Wright C. Different interpretations of 'evidence' and implications for the Canadian healthcare system. In: Flood CM, Roach K, Sossin L, editors. Access to care: access to justice: the legal debate over private health insurance in Canada. Toronto (ON): University of Toronto Press; 2005. p. 221-222
14. Walsh and Ors v. Pharmac, [2008] NZHC 441.
15. Provider selection protocols. Wellington (New Zealand): New Zealand Ministry of Health; 2005. p. 9-10.
16. Richards M. Improving access to medicines for NHS patients. London (England): Secretary of State for Health; 2008.
17. The Bristol Royal Infirmary Inquiry. Learning from Bristol: the report of the public inquiry into children's heart surgery at the Bristol Royal Infirmary 1984-1995. London (England): Secretary of State for Health; 2001.
18. Chaoulli v. Quebec, [2005] 1 S.C.R. 791.
19. Cancer Care Ontario. Report of the Provincial Working Group on the Delivery of Oncology Medications for Private Payment in Ontario Hospitals. Toronto (ON): Cancer Care Ontario; 2006.
20. Cancer Care Ontario. Unfunded intravenous cancer drugs. Available: http://cancercare .on.ca/cms/One.aspx?portalid=1377&pageid=11822# (accessed 2010 Jan. 29).
21. The Canadian Charter of Rights and Freedoms, Part I of the Constitution Act, 1982, being Schedule B to the Canada Act 1982 (U.K.), 1982, c 11.
22. R. v. Morgentaler, [1988] 1 S.C.R. 30.